Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Global Dry Eye Syndrome Treatment Market – Industry Trends and Forecast to 2029

Pharmaceutical | Upcoming Report | Apr 2022 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

Global Dry Eye Syndrome Treatment Market, By Product Type (Tear Stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Treatment (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Diagnosis (Comprehensive Eye Exam, Schirmer Test, Tear Osmolarity Test, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2029


Market Analysis and Size

In recent years, the dry eye syndrome treatment market is anticipated to grow rapidly during the forecast period. Dry eye illness affects a large percentage of the global population (from middle age to elderly age). According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. From 9.3 percent in 2020 to roughly 16.0 percent in 2050, the proportion of the population aged 65 and up is predicted to rise. The elderly population is expected to grow, and this group will need to be accommodated.

Data Bridge Market Research analyses that the dry eye syndrome treatment market was valued at USD 5,878.88 million in 2021 and is expected to reach USD 11,904.51 million by 2029, registering a CAGR of 9.22% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a condition in which the surface of the affected person's eyes lacks lubrication or moisture. It's a common ailment that can strike anyone at any time. Aching and burning sensations, sore eyes, red eyes, weary eyes, itchy eyes, photophobia, and other symptoms of dry eye can occur. Watery eyes can also be a symptom, as the dry surface of the eyes over-stimulates the production of the watery component of tears to compensate for the dryness.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Tear stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Treatment (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Eli Lilly and Company (US), AstraZeneca (UK), Novartis AG (Switzerland), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Merck & Co., Inc. (US), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Merck KGaA (Germany), Otsuka America Pharmaceutical, Inc. (US), Akorn Operating Company LLC (US), Allostera Pharma Inc. (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT Pharmaceuticals (New Zealand), Novaliq GmbH (Germany)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Dry Eye Syndrome Treatment Market Dynamics

Drivers

  • Increasing prevalence of dry eyes among people

The rising prevalence of dry eyes among people is a primary driver of the dry eye syndrome treatment market's growth. Thyroid disorders, lupus, Sjogren's syndrome, diabetes, rheumatoid arthritis, scleroderma, and others are the various diseases contributing to the high prevalence of dry eyes among people.    

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of dry eye syndrome treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the dry eye syndrome treatment market. Additionally, high disposable income and increasing demand for standard treatment will result in the expansion of dry eye syndrome treatment market. Changing dietary pattern and sedentary lifestyle are the factors that will influence the market dynamics during the forecast period. Along with this, rising geriatric population and increasing awareness about dry eye problems among people will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the dry eye syndrome treatment market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the dry eye syndrome treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the dry eye syndrome treatment market. Additionally, strict drug approval mechanisms of testing bodies resulting in the delay of launch of new drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This dry eye syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dry eye syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Dry eye syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Dry Eye Syndrome Treatment Market

Since its emergence in December 2019, the COVID-19  virus had spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The dry eye syndrome treatment market was negatively impacted by COVID-19. The sudden rise in coronavirus infections caused healthcare staff to focus on coronavirus management, obscuring other instances. There was a shortage of eye care drugs on the market due to restrictions on the flow of products and people. Furthermore, it resulted in a decrease in the number of individuals seeking treatment in hospitals and clinics. However, internet medical consultation and pharmaceutical sales have seen a surge in popularity. Following the COVID-19 relaxations, the market is quickly recovering.

Recent Development

  • In January 2022, Sun Pharma announced the launch of dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nanomicellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.

Global Dry Eye Syndrome Treatment Market Scope

The dry eye syndrome treatment market is segmented on the basis of product type, dosage type, treatment, diagnosis, dose, medication type, container type, packaging type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Tear stimulators
  • Artificial Tears
  • Secretagogue
  • Others

Dosage Type

  • Liquid
  • Semi-solid
  • Others

Treatment

  • Lubricating Agent
  • Cholinergics
  • Anti-Inflammatory
  • Anti-Infectives
  • Anti-Allergics
  • Others

Diagnosis

  • Comprehensive Eye Exam
  • Schirmer Test
  • Tear Osmolarity Test
  • Others

Dose

  • Unit dose
  • Multi-dose

Medication Type

Container Type

  • Unit-Dose Vials
  • Bottles
  • Tubes

Packaging Type

  • Plastic
  • Aluminium
  • Glass

Type

  • Brands
  • Generics

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the dry eye syndrome treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Dry Eye Syndrome Treatment Market Regional Analysis/Insights

The Dry eye syndrome treatment market is analysed and market size insights and trends are provided by country, product type, dosage type, treatment, diagnosis, dose, medication type, container type, packaging type, type, end-users and distribution channel as referenced above.

The countries covered in the Dry eye syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the dry eye syndrome treatment market because of the growing prevalence of dry eye syndrome in this region. Additionally, growing focus of major key players on novel technology will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Dry Eye Syndrome Treatment Market Share Analysis

The Dry eye syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dry eye syndrome treatment market.

Some of the major players operating in the dry eye syndrome treatment market are:

  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • AstraZeneca (UK)
  • Johnson & Johnson Private Limited (US)
  • Abbott (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (US)
  • Otsuka America Pharmaceutical, Inc. (US)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Merck KGaA (Germany)
  • Allergan (Ireland)
  • Akorn Operating Company LLC (US)
  • Allostera Pharma Inc. (Canada)
  • I-Med Pharma Inc. (Canada)
  • Santen Pharmaceuticals Co. Ltd., (Japan)
  • AFT Pharmaceuticals (New Zealand)
  • Novaliq GmbH (Germany)   


SKU-

Table of Content

Please fill in the below form for detailed Table of Content

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Table

Please fill in the below form for detailed List of Table

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Figure

Please fill in the below form for detailed List of Figure

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

View Infographics

Please fill in the below form for detailed Infographics

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country
CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19